Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jae-Cheol Lee

Showing results (181-190 of 226) with videos related to

Pageof 23
Sort By:
Oncotarget|March 17, 2016
Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerJi Hyun Park, Yun Jung Choi, Seon Ye Kim, et al.
Journal of Korean Medical Science|February 16, 2006
Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancerKwang Hyun Paik, Yeon Hee Park, Baek-Yeol Ryoo, et al.
Biochemical and Biophysical Research Communications|October 7, 2022
Generation of genetically engineered mice for lung cancer with mutant EGFRDa-Som Kim, Wonjun Ji, Dong Ha Kim, et al.
Clinical and Molecular Hepatology|April 3, 2015
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cellsHa Ra Gu, Su Cheol Park, Su Jin Choi, et al.
Biochemical and Biophysical Research Communications|March 3, 2012
Requirement of protein l-isoaspartyl O-methyltransferase for transcriptional activation of trefoil factor 1 (TFF1) gene by estrogen receptor alphaJong Woo Park, Jae Cheol Lee, Shin Won Ha, et al.
Cancer Research and Treatment|March 6, 2025
The Profile of Gut Microbiota in Carcinogenesis Driven by Mutant EGFR in Non-Small Cell Lung CancerDa-Som Kim, Eun Hye Kim, Ji Yong Kim, et al.
The Journal of Pathology|September 2, 2017
Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosisJi An Hwang, Deokhoon Kim, Sung-Min Chun, et al.
Molecular Oncology|October 24, 2018
Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancerDong Ha Kim, Yun Jung Choi, Ki Jung Sung, et al.
Thoracic Cancer|December 12, 2025
Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort StudyYechan Song, Myeong Geun Choi, Yeon Joo Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|April 18, 2009
18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysisIm Il Na, Byung Hyun Byun, Kyeong Min Kim, et al.
Pageof 23

Showing results (181-190 of 226) with videos related to

Sort By:
Pageof 23
Oncotarget|March 17, 2016
Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancerJi Hyun Park, Yun Jung Choi, Seon Ye Kim, et al.
Journal of Korean Medical Science|February 16, 2006
Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancerKwang Hyun Paik, Yeon Hee Park, Baek-Yeol Ryoo, et al.
Biochemical and Biophysical Research Communications|October 7, 2022
Generation of genetically engineered mice for lung cancer with mutant EGFRDa-Som Kim, Wonjun Ji, Dong Ha Kim, et al.
Clinical and Molecular Hepatology|April 3, 2015
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cellsHa Ra Gu, Su Cheol Park, Su Jin Choi, et al.
Biochemical and Biophysical Research Communications|March 3, 2012
Requirement of protein l-isoaspartyl O-methyltransferase for transcriptional activation of trefoil factor 1 (TFF1) gene by estrogen receptor alphaJong Woo Park, Jae Cheol Lee, Shin Won Ha, et al.
Cancer Research and Treatment|March 6, 2025
The Profile of Gut Microbiota in Carcinogenesis Driven by Mutant EGFR in Non-Small Cell Lung CancerDa-Som Kim, Eun Hye Kim, Ji Yong Kim, et al.
The Journal of Pathology|September 2, 2017
Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosisJi An Hwang, Deokhoon Kim, Sung-Min Chun, et al.
Molecular Oncology|October 24, 2018
Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancerDong Ha Kim, Yun Jung Choi, Ki Jung Sung, et al.
Thoracic Cancer|December 12, 2025
Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort StudyYechan Song, Myeong Geun Choi, Yeon Joo Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|April 18, 2009
18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysisIm Il Na, Byung Hyun Byun, Kyeong Min Kim, et al.
Pageof 23